USANA Health Sciences Inc. (NYSE:USNA) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a report released on Wednesday.
According to Zacks, “USANA Health Sciences Inc. develops and manufactures high-quality nutritional, personal care and weight management products. The company’s three primary product lines consist of nutritional, personal care and weight management products. The company’s products are distributed primarily through a network marketing system. “
Separately, DA Davidson lifted their target price on USANA Health Sciences from $135.00 to $150.00 and gave the stock a “neutral” rating in a report on Thursday, July 28th. Three investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. USANA Health Sciences presently has an average rating of “Buy” and a consensus target price of $149.11.
USANA Health Sciences (NYSE:USNA) opened at 136.21 on Wednesday. The stock’s 50 day moving average price is $135.99 and its 200-day moving average price is $125.47. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of 17.95 and a beta of 1.16. USANA Health Sciences has a one year low of $92.00 and a one year high of $142.96.
USANA Health Sciences (NYSE:USNA) last posted its earnings results on Tuesday, July 26th. The company reported $2.07 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.05 by $0.02. The firm had revenue of $258.50 million for the quarter, compared to analyst estimates of $256.66 million. USANA Health Sciences had a return on equity of 34.15% and a net margin of 10.07%. The company’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same period in the previous year, the company posted $1.92 earnings per share. Analysts forecast that USANA Health Sciences will post $8.10 earnings per share for the current year.
In related news, insider Deborah Woo sold 5,041 shares of USANA Health Sciences stock in a transaction dated Thursday, August 18th. The stock was sold at an average price of $131.15, for a total value of $661,127.15. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Global Ltd Gull sold 10,000 shares of USANA Health Sciences stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $134.67, for a total value of $1,346,700.00. Following the completion of the sale, the insider now directly owns 6,329,110 shares in the company, valued at approximately $852,341,243.70. The disclosure for this sale can be found here. 57.00% of the stock is owned by insiders.
Several hedge funds have recently added to or reduced their stakes in USNA. Norges Bank bought a new stake in USANA Health Sciences during the fourth quarter worth about $8,981,000. Emerald Acquisition Ltd. bought a new stake in USANA Health Sciences during the second quarter worth about $4,619,000. Old Mutual Global Investors UK Ltd. increased its stake in USANA Health Sciences by 174.8% in the second quarter. Old Mutual Global Investors UK Ltd. now owns 59,105 shares of the company’s stock worth $6,586,000 after buying an additional 37,595 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its stake in USANA Health Sciences by 15.8% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 163,822 shares of the company’s stock worth $18,255,000 after buying an additional 22,326 shares in the last quarter. Finally, Teachers Advisors Inc. increased its stake in USANA Health Sciences by 30.6% in the first quarter. Teachers Advisors Inc. now owns 87,383 shares of the company’s stock worth $10,610,000 after buying an additional 20,496 shares in the last quarter. 41.86% of the stock is currently owned by institutional investors and hedge funds.
About USANA Health Sciences
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. It operates as a direct selling company in approximately two geographic regions: Americas and Europe, and Asia Pacific, which includes approximately three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.